[Cyberknife and benign pathologies].
Conventional radiotherapy is known to be an effective treatment approach even for "benign" pathologies. However, this kind of treatment yields a high potential for side effects. The Cyberknife, a robotic stereotactic radiotherapy device, enables to offset a large proportion of the disadvantages encountered with conventional radiotherapy essentially through the high precision of dose administration and sparing of healthy tissues. Therefore, it seems to be a treatment of choice in the approach of some benign intracranial diseases. We review published data on indications and outcome of Cyberknife for intracranial "non-malignant" disease.
Université de Liège, Belgique.
F
F
Lallemand
Z L
ZL
Janvary
N
N
Jansen
Ph
P
Coucke
D000236:Adenoma / Q000473:pathology / Q000601:surgery; D004833:Epilepsy, Temporal Lobe / Q000473:pathology / Q000601:surgery; D005925:Glomus Jugulare Tumor / Q000473:pathology / Q000601:surgery; D006801:Humans; D002538:Intracranial Arteriovenous Malformations / Q000473:pathology / Q000601:surgery; D008577:Meningeal Neoplasms / Q000473:pathology / Q000601:surgery; D008579:Meningioma / Q000473:pathology / Q000601:surgery; D010911:Pituitary Neoplasms / Q000473:pathology / Q000601:surgery; D011788:Quality of Life; D018787:Radiation Oncology / Q000295:instrumentation; D016634:Radiosurgery / Q000295:instrumentation / Q000379:methods*; D011879:Radiotherapy Dosage; D016896:Treatment Outcome; D014277:Trigeminal Neuralgia / Q000473:pathology / Q000601:surgery